SCHEMBL18156891

SCHEMBL18156891

CC(C)(O)c1ccc(N)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 4/20 0.44
TSHR P16473 2/20 0.38
GLA P06280 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
CASP1 P29466 2/20 0.34
PDE10A Q9Y233 1/20 0.34
PGR P06401 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HSD11B1 P28845 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
GFER P55789 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAP4K4 O95819 1/20 0.31
MINK1 Q8N4C8 1/20 0.31
TNIK Q9UKE5 1/20 0.31
KCNN4 O15554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2716570 0.83 TSHR (0.42) KIF11TSHRGLAPOLBGAA
SCHEMBL2570700 0.83 KIF11 (0.47) KIF11TSHRGLAPOLBGAA
SCHEMBL18999755 0.82 KIF11 (0.44) KIF11TSHRGLAPOLBGAA
SCHEMBL31481037 0.81 KIF11 (0.50) KIF11TSHRGLAPOLBGAA
SCHEMBL12982710 0.79 KIF11 (0.41) KIF11TSHRGLAPOLBGAA
SCHEMBL1507033 0.78 KCNN4 (0.43) GAAALDH1A1LMNAKCNN4
SCHEMBL29727285 0.78 KCNN4 (0.43) GAAALDH1A1LMNAKCNN4
SCHEMBL13858152 0.78 KIF11 (0.47) KIF11TSHRGLAPOLBGAA
SCHEMBL28402360 0.78 TSHR (0.55) KIF11TSHRGLAPOLBGAA
SCHEMBL30619303 0.78 TSHR (0.55) KIF11TSHRGLAPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025054339-A1 TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT ARCUS BIOSCIENCES, INC. (US) 2025-03-13 WO disclosed
US-10011566-B2 Compounds ASTRAZENECA AB (SE) 2018-07-03 US disclosed
US-9738600-B2 ROR gamma (RORγ) modulators LEAD PHARMA CEL MODELS IP B.V. (NL) 2017-08-22 US disclosed
US-20170166527-A1 Novel Compounds ASTRAZENECA AB (SE) 2017-06-15 US disclosed
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011566-B2 Compounds RORC, RORB, RORA KIF11 2375/4885TSHR 953/4885GLA 2175/4885
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS RORC, RORA, RORB KIF11 570/4885TSHR 167/4885GLA 3523/4885
US-20170166527-A1 Novel Compounds RORC, RORB, RORA KIF11 2594/4885TSHR 1099/4885GLA 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.